IGF2BP1 and Miyoshi myopathy: A 2023 study showed that IGF2BP1 acts as a post-transcriptional enhancer of cell division cycle 5-like (CDC5L) protein in an N6-methyladenosine reader manner to promote the proliferation of MM cells with + 1q abnormalities; high CDC5L expression also predicts poorer prognoses in this patient population [34].